BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36471194)

  • 1. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
    Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
    J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
    Haggerty T; Turiano NA; Turner T; Dekeseredy P; Sedney CL
    Addict Sci Clin Pract; 2022 Dec; 17(1):72. PubMed ID: 36517926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
    Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
    J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care.
    Salvador JG; Myers OB; Bhatt SR; Jacobsohn V; Lindsey L; Alkhafaji RS; Rishel Brakey H; Sussman AL
    Subst Abus; 2023 Oct; 44(4):282-291. PubMed ID: 37902036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention With Medication for Opioid Use Disorder: The Role of the Primary Care Relationship.
    Munger J; Back E
    J Addict Med; 2022 Sep-Oct 01; 16(5):577-580. PubMed ID: 35020699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "The Only Reason I Am Willing to Do It at All": Evaluation of VA's SUpporting Primary care Providers in Opioid Risk reduction and Treatment (SUPPORT) Center.
    Williams EC; Frost MC; Danner AN; Lott AMK; Achtmeyer CE; Hood CL; Malte CA; Saxon AJ; Hawkins EJ
    J Addict Med; 2024 May-Jun 01; 18(3):248-255. PubMed ID: 38385548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
    Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
    Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 14. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder.
    Cochran G; Cole ES; Sharbaugh M; Nagy D; Gordon AJ; Gellad WF; Pringle J; Bear T; Warwick J; Drake C; Chang CH; DiDomenico E; Kelley D; Donohue J
    J Addict Med; 2022 Mar-Apr 01; 16(2):e87-e96. PubMed ID: 33973921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
    Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
    BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
    Dowd WN; Barch DH; Seibert JH; Mark TL
    J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
    Ober AJ; Dopp AR; Clingan SE; Curtis ME; Lin C; Calhoun S; Larkins S; Black M; Hanano M; Osterhage KP; Baldwin LM; Saxon AJ; Hichborn EG; Marsch LA; Mooney LJ; Hser YI
    J Subst Use Addict Treat; 2024 Jan; 156():209194. PubMed ID: 37863356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.